18355-74-3

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2,3-DIFLUOROBENZOATE is used as a key intermediate in the preparation of tricyclic carboxamides, which are known as modulators of the Hepatitis B core protein. These modulators have the potential to treat Hepatitis B virus infections by targeting the core protein, an essential component of the virus life cycle.
In the synthesis of tricyclic carboxamides, METHYL 2,3-DIFLUOROBENZOATE plays a crucial role in the formation of the desired molecular structure, which is responsible for the biological activity of the final product. The presence of fluorine atoms in the molecule contributes to the enhanced lipophilicity and metabolic stability of the resulting compounds, making them more effective in treating Hepatitis B infections.
Furthermore, the unique properties of METHYL 2,3-DIFLUOROBENZOATE can also be exploited in the development of other pharmaceutical agents, such as antibiotics, anti-inflammatory drugs, and central nervous system agents. Its versatility as a synthetic intermediate allows for the creation of a wide range of drug candidates with diverse therapeutic applications.

InChI:InChI=1/C8H6F2O2/c1-12-8(11)5-3-2-4-6(9)7(5)10/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 4519-39-5 2,3-difluorobenzoic acid 
• 18355-73-2 2,3-difluorobenzoyl chloride 

Downstream Products

• 845868-03-3 2-(1-benzenesulfonyl-1H-pyrrol-3-yl)-1-(2,3-difluoro-phenyl)-ethanone 
• 267880-87-5 3-(2,3-difluorophenyl)-3-oxopropanenitrile 
• 1621256-23-2 C₁₄H₁₇BF₂O₄ 
• 1620579-46-5 (2,3-difluorophenyl)dideuteromethanol 
• 387358-53-4 2,3-difluorobenzohydrazide 
• 1307313-08-1 [2-[4-[(2-chloro-4,4-difluoro-4,5-dihydrospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methanol 
• 1307314-56-2 methyl 2-[4-[(2-chloro-4,4-difluoro-4,5-dihydrospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorobenzoate 
• 1307314-58-4 2-[4-[(2-chloro-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methyl-pyrazol-1-yl]-3-fluoro-benzaldehyde 
• 1307314-07-3 methyl 3-fluoro-2-(4-formyl-3-methylpyrazol-1-yl)benzoate 
• 1307313-69-4 [2-[4-[(2-chloro-4,4-difluoro-4,5-dihydrospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]-N-methylmethanamine (L)-tartrate 
• 1307313-68-3 [2-[4-[(2-chloro-4,4-difluoro-4,5-dihydrospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]-N-methylmethanamine 
• 1307313-09-2 [2-[4-[(2-chloro-4,4-difluoro-4,5-dihydrospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methanol (L)-tartrate 

Relevant academic research and scientific papers

SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents

Recently, the fungal sphingolipid glucosylceramide (GlcCer) synthesis has emerged as a highly promising new target for drug discovery of next-generation antifungal agents, and we found two aromatic acylhydrazones as effective inhibitors of GlcCer synthesis based on HTP screening. In the present work, we have designed libraries of new aromatic acylhydrazones, evaluated their antifungal activities (MIC80 and time-kill profile) against C. neoformans, and performed an extensive SAR study, which led to the identification of five promising lead compounds, exhibiting excellent fungicidal activities with very large selectivity index. Moreover, two compounds demonstrated broad spectrum antifungal activity against six other clinically relevant fungal strains. These five lead compounds were examined for their synergism/cooperativity with five clinical drugs against seven fungal strains, and very encouraging results were obtained; e.g., the combination of all five lead compounds with voriconazole exhibited either synergistic or additive effect to all seven fungal strains.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS

An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.